Answers are grounded in this paper and cite their sources.
The decline in NSAID-associated GI mortality is likely due to increased PPI use, highlighting the ongoing risk of low-dose aspirin which accounts for a third of these deaths.
Although gastrointestinal (GI) morbidity and mortality from NSAIDs continues to be a significant problem, this study by Lanas et al. indicates that the magnitude of the concern is declining. Explanations for this reduction are more likely related to the increased use of proton pump inhibitors (PPIs) than to the introduction of COX-2 inhibitors. This study further reveals that one-third of NSAIDs' GI mortality comes from low-dose, daily aspirin. Another important contribution derived from this report is a more reliable estimate of NSAIDs' lower GI clinical consequences than previously available.
No takes yet. Share an insight, caveat, or question.
Byron Cryer (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: